31 our catalyst dx ® analyzer is our latest g eneration chemistry analyzer , which was launched in 2008. we place our catalyst dx ® analyzer through sales , leases , rental and other programs . in addition , we continue to place vettest ® instruments through sales , lease , rental and other programs , with substantially all of our revenues from that product line currently derived from consumable sales . as of december 31 , 2012 , these two chemistry analyzers provided for a combined active installed base of approximately 33,000 units . a substantial portion of 2012 catalyst dx ® analyzer placements were to customers who had been using instruments from one of our competitors , sometimes referred to as competitive accounts . generally , placement of an instrument with a competitive account is more attractive as the entire consumable stream associated with that placement represents incremental revenue , whereas the consumable stream associated with a catalyst dx ® placement at a vettest ® customer substitutes a catalyst dx ® consumable stream for a vettest ® consumable stream . nonetheless , we have found that the consumables revenues increase when a customer upgrades from a vettest ® analyzer to a catalyst dx ® analyzer due to the superior capability and flexibility of the catalyst dx ® , which leads to additional testing by the customer . the procyte dx ® analyzer is our latest generation hematology analyzer , which we launched in the third quarter of 2010. in addition we sell the lasercyte ® analyzer and vetautoread analyzer . as of december 31 , 2012 these three hematology analyzers provided for a combined active installed base of approximately 24,000 units . a substantial portion of procyte dx ® analyzer placements continue to be made at veterinary clinics that elect to upgrade from their lasercyte ® analyzer to a procyte dx ® analyzer . however , an increasing number of placements have been made at competitive accounts since the launch of this instrument in 2010. while customers continue to upgrade from their lasercyte ® analyzer to a procyte dx ® analyzer , we continue to place a substantial number of lasercyte ® instruments , both new and refurbished , as trade-ups from the vetautoread analyzer and at new and competitive accounts . in 2012 , a significant number of lasercyte ® instruments that were placed were refurbished instruments that had been received in trade in the sale of a procyte dx ® analyzer . as we continue to experience growth in placements of procyte dx ® analyzers and in sales of related consumables , we expect this growth to be partly offset by a decline in placements of lasercyte ® and vetautoread analyzers and in sales of related consumables . our long-term success in this area of our business is dependent upon new customer acquisition , customer loyalty and retention and customer utilization of existing and new assays introduced for use on our analyzers . we continuously seek opportunities to enhance the care that veterinary professionals give to their patients and clients through supporting the implementation of real-time care testing workflows , which is performing tests and sharing test results with the client at the time of the patient visit . our latest generation of chemistry and hematology instruments demonstrates this commitment by offering enhanced ease of use , faster time to results , greater sample throughput , broader test menu and connectivity to various information technology platforms that enhance the value of the diagnostic information generated by the instruments . utilization can increase due to a greater number of patient samples being run or to an increase in the number of tests being run per patient sample . our strategy is to increase both drivers . to increase utilization , we seek to educate veterinarians about best medical practices that emphasize the importance of chemistry and hematology testing at the point-of-care for a variety of diagnostic purposes . in connection with the purchase of instruments , we also offer protocol-based rebate incentives when customers utilize the broad testing functionality of our analyzers . in addition , we provide marketing tools and consultative services that help drive efficiencies in veterinary practice processes and allow practices to increase the number of clients they see on a daily basis . with all of our instrument product lines , we seek to differentiate our products from our competitors ' products based on time-to-result , ease-of-use , throughput , breadth of diagnostic menu , flexibility of menu selection , accuracy , reliability , ability to handle compromised samples , analytical capability of software , integration with the idexx vetlab ® station , client communications capabilities , education and training , and superior sales and customer service . our success depends , in part , on our ability to differentiate our products in a way that justifies a premium price . 32 rapid assay products . our rapid assay strategy is to develop , manufacture , market and sell proprietary tests that address important medical needs for particular diseases prevalent in the companion animal population . we seek to differentiate our tests from those of other in-clinic test providers and reference laboratory diagnostic service providers through ease-of-use and superior performance , including by providing our customers with combination tests that test a single sample for multiple analytes . we further augment our product development and customer service efforts with sales and marketing programs that enhance medical awareness and understanding regarding certain diseases and the importance of diagnostic testing . we also seek to enhance the attractiveness of our tests by providing the snapshot dx ® analyzer , which automatically reads certain snap ® test results , and records those results in the electronic medical record . this promotes practice efficiency by eliminating manual entry of test results in patient records and also helps ensure that the services are recorded and accurately invoiced . story_separator_special_tag if these up-front incentives are subsequently utilized to purchase idexx vetlab ® instruments , digital radiography systems or cornerstone ® practice management systems , product revenue and cost is deferred and recognized over the term of the customer agreement as products and services are provided to the customer . we monitor customer purchases over the term of their agreement to assess the realizability of our capitalized customer acquisition costs . for the years ended december 31 , 2012 , 2011 and 2010 , impairments of customer acquisition costs were immaterial . idexx vetlab ® instrument marketing programs . our instrument marketing programs require the customer to enroll at the time of instrument purchase and offer customers the opportunity to earn incentives in future periods based on the volume of the products they purchase and utilize over the term of the program . these arrangements are considered meas in accordance with our revenue recognition policy stated above . revenue reductions related to instrument marketing programs are recorded based on an estimate of customer purchase and utilization levels and the incentive the customer will earn over the term of the program . our estimates are based on historical experience and the specific terms and conditions of the marketing program and require us to apply judgment to approximate future product purchases and utilization . differences between our estimates and actual incentives earned are accounted for as a change in estimate . these differences were not material for the years ended december 31 , 2012 , 2011 and 2010. at 36 december 31 , 2012 , a 5 % change in our estimate of future customer utilization would increase or reduce revenue by approximately $ 0.3 million . reagent rental programs . our reagent rental programs provide our customers the right to use our instruments in consideration for multi-year agreements to purchase annual minimum amounts of consumables . no instrument revenue is recognized at the time of instrument installation . we recognize a portion of the revenue allocated to the instrument concurrent with the future sale of consumables . we determine the amount of revenue allocated from the consumable to the instrument based on vsoe and determine the rate of instrument revenue recognition in proportion to the customer 's minimum volume commitment . the cost of the instrument is reclassified from inventory to equipment and charged to cost of product revenue on a straight-line basis over the term of the rental agreement . idexx points may be applied against the purchase price of idexx products and services purchased in the future or applied to trade receivables due to us . idexx points that have not yet been used by customers are classified as a liability until use or expiration occurs . we estimate the amount of idexx points expected to expire , or breakage , based on historical expirations and we recognize the estimated benefit of breakage as idexx points are issued to customers . on november 30 of each year , unused idexx points earned before january 1 of the prior year generally expire and any variance from the breakage estimate is accounted for as a change in estimate . this variance was not material for the years ended december 31 , 2012 , 2011 and 2010. future market conditions and changes in product offerings may cause us to change marketing strategies to increase or decrease customer incentive offerings , possibly resulting in incremental reductions of revenue in future periods as compared to reductions in the current or prior periods . additionally , certain customer programs require us to estimate , based on historical experience , and apply judgment to approximate the number of customers who will actually redeem the incentive . in determining estimated revenue reductions we utilize data supplied from distributors and collected directly from end-users , which includes the volume of qualifying products purchased and the number of qualifying tests run as reported to us by end-users via idexx smartservice tm , a secure i nternet link that enables us to extract data and provide diagnostic service and support for certain idexx vetlab ® instruments through remote access . differences between estimated and actual customer participation in programs may impact the amount and timing of revenue recognition . following is a summary of revenue reductions , net recorded in connection with our customer programs for the years ended december 31 , 2012 , 2011 and 2010 ( in thousands ) : replace_table_token_4_th 37 at december 31 , 2012 , 2011 and 2010 , the total accrued revenue reductions were $ 36.6 million , $ 37.8 million and $ 23.3 million , respectively . accrued customer programs are included within accrued liabilities and other long-term liabilities , depending on the anticipated settlement date , in the consolidated balance sheets included in this annual report on form 10-k. following is a summary of changes in the accrual for estimated revenue reductions attributable to customer marketing and incentive programs and the ending accrued customer programs balance for the years ended december 31 , 2012 , 2011 and 2010 ( in thousands ) : replace_table_token_5_th inventory valuation we write down the carrying value of inventory for estimated obsolescence by an amount equal to the difference between the cost of inventory and the estimated market value when warranted based on assumptions of future demand , market conditions , remaining shelf life , or product functionality . if actual market conditions or results of estimated functionality are less favorable than those we estimated , additional inventory write-downs may be required , which would have a negative effect on results of operations . valuation of goodwill and other intangible assets a significant portion of the purchase price for acquired businesses is generally assigned to intangible assets . intangible assets other than goodwill are initially valued at fair value . if a quoted price in an active market for the identical asset is not readily available at the measurement date , the fair value of the intangible asset

liquidity and capital resources we fund the capital needs of our business through cash on hand , funds generated from operations , and amounts available under our credit facility . at december 31 , 2012 and december 31 , 2011 , we had $ 224.0 million and $ 183.9 million , respectively , of cash and cash equivalents , and working capital of $ 163.2 million and $ 87.3 million , respectively . additionally , at december 31 , 2012 , we had remaining borrowing availability of $ 87 million under our $ 300 million credit facility . we believe that , if necessary , we could obtain additional borrowings at prevailing market interest rates to fund our growth objectives . we further believe that current cash and cash equivalents , funds generated from operations , and available borrowings will be sufficient to fund our operations , capital purchase requirements , and strategic growth needs for the next twelve months , and that these resources will be sufficient in the long term to fund our business as currently conducted . we consider the majority of the operating earnings of certain non-u.s. subsidiaries to be indefinitely invested outside the u.s. changes to this position could have adverse tax consequences . we manage our worldwide cash requirements considering available funds among all of our subsidiaries . our foreign cash balances are generally available without restrictions to fund ordinary business operations outside the u.s. of our total cash and cash equivalents at december 31 , 2012 , approximately $ 222.4 million was held by our foreign subsidiaries and was subject to material repatriation tax effects .


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```liquidity and capital resources we fund the capital needs of our business through cash on hand , funds generated from operations , and amounts available under our credit facility . at december 31 , 2012 and december 31 , 2011 , we had $ 224.0 million and $ 183.9 million , respectively , of cash and cash equivalents , and working capital of $ 163.2 million and $ 87.3 million , respectively . additionally , at december 31 , 2012 , we had remaining borrowing availability of $ 87 million under our $ 300 million credit facility . we believe that , if necessary , we could obtain additional borrowings at prevailing market interest rates to fund our growth objectives . we further believe that current cash and cash equivalents , funds generated from operations , and available borrowings will be sufficient to fund our operations , capital purchase requirements , and strategic growth needs for the next twelve months , and that these resources will be sufficient in the long term to fund our business as currently conducted . we consider the majority of the operating earnings of certain non-u.s. subsidiaries to be indefinitely invested outside the u.s. changes to this position could have adverse tax consequences . we manage our worldwide cash requirements considering available funds among all of our subsidiaries . our foreign cash balances are generally available without restrictions to fund ordinary business operations outside the u.s. of our total cash and cash equivalents at december 31 , 2012 , approximately $ 222.4 million was held by our foreign subsidiaries and was subject to material repatriation tax effects .
```    
 Suspicious Activity Report : 31 our catalyst dx ® analyzer is our latest g eneration chemistry analyzer , which was launched in 2008. we place our catalyst dx ® analyzer through sales , leases , rental and other programs . in addition , we continue to place vettest ® instruments through sales , lease , rental and other programs , with substantially all of our revenues from that product line currently derived from consumable sales . as of december 31 , 2012 , these two chemistry analyzers provided for a combined active installed base of approximately 33,000 units . a substantial portion of 2012 catalyst dx ® analyzer placements were to customers who had been using instruments from one of our competitors , sometimes referred to as competitive accounts . generally , placement of an instrument with a competitive account is more attractive as the entire consumable stream associated with that placement represents incremental revenue , whereas the consumable stream associated with a catalyst dx ® placement at a vettest ® customer substitutes a catalyst dx ® consumable stream for a vettest ® consumable stream . nonetheless , we have found that the consumables revenues increase when a customer upgrades from a vettest ® analyzer to a catalyst dx ® analyzer due to the superior capability and flexibility of the catalyst dx ® , which leads to additional testing by the customer . the procyte dx ® analyzer is our latest generation hematology analyzer , which we launched in the third quarter of 2010. in addition we sell the lasercyte ® analyzer and vetautoread analyzer . as of december 31 , 2012 these three hematology analyzers provided for a combined active installed base of approximately 24,000 units . a substantial portion of procyte dx ® analyzer placements continue to be made at veterinary clinics that elect to upgrade from their lasercyte ® analyzer to a procyte dx ® analyzer . however , an increasing number of placements have been made at competitive accounts since the launch of this instrument in 2010. while customers continue to upgrade from their lasercyte ® analyzer to a procyte dx ® analyzer , we continue to place a substantial number of lasercyte ® instruments , both new and refurbished , as trade-ups from the vetautoread analyzer and at new and competitive accounts . in 2012 , a significant number of lasercyte ® instruments that were placed were refurbished instruments that had been received in trade in the sale of a procyte dx ® analyzer . as we continue to experience growth in placements of procyte dx ® analyzers and in sales of related consumables , we expect this growth to be partly offset by a decline in placements of lasercyte ® and vetautoread analyzers and in sales of related consumables . our long-term success in this area of our business is dependent upon new customer acquisition , customer loyalty and retention and customer utilization of existing and new assays introduced for use on our analyzers . we continuously seek opportunities to enhance the care that veterinary professionals give to their patients and clients through supporting the implementation of real-time care testing workflows , which is performing tests and sharing test results with the client at the time of the patient visit . our latest generation of chemistry and hematology instruments demonstrates this commitment by offering enhanced ease of use , faster time to results , greater sample throughput , broader test menu and connectivity to various information technology platforms that enhance the value of the diagnostic information generated by the instruments . utilization can increase due to a greater number of patient samples being run or to an increase in the number of tests being run per patient sample . our strategy is to increase both drivers . to increase utilization , we seek to educate veterinarians about best medical practices that emphasize the importance of chemistry and hematology testing at the point-of-care for a variety of diagnostic purposes . in connection with the purchase of instruments , we also offer protocol-based rebate incentives when customers utilize the broad testing functionality of our analyzers . in addition , we provide marketing tools and consultative services that help drive efficiencies in veterinary practice processes and allow practices to increase the number of clients they see on a daily basis . with all of our instrument product lines , we seek to differentiate our products from our competitors ' products based on time-to-result , ease-of-use , throughput , breadth of diagnostic menu , flexibility of menu selection , accuracy , reliability , ability to handle compromised samples , analytical capability of software , integration with the idexx vetlab ® station , client communications capabilities , education and training , and superior sales and customer service . our success depends , in part , on our ability to differentiate our products in a way that justifies a premium price . 32 rapid assay products . our rapid assay strategy is to develop , manufacture , market and sell proprietary tests that address important medical needs for particular diseases prevalent in the companion animal population . we seek to differentiate our tests from those of other in-clinic test providers and reference laboratory diagnostic service providers through ease-of-use and superior performance , including by providing our customers with combination tests that test a single sample for multiple analytes . we further augment our product development and customer service efforts with sales and marketing programs that enhance medical awareness and understanding regarding certain diseases and the importance of diagnostic testing . we also seek to enhance the attractiveness of our tests by providing the snapshot dx ® analyzer , which automatically reads certain snap ® test results , and records those results in the electronic medical record . this promotes practice efficiency by eliminating manual entry of test results in patient records and also helps ensure that the services are recorded and accurately invoiced . story_separator_special_tag if these up-front incentives are subsequently utilized to purchase idexx vetlab ® instruments , digital radiography systems or cornerstone ® practice management systems , product revenue and cost is deferred and recognized over the term of the customer agreement as products and services are provided to the customer . we monitor customer purchases over the term of their agreement to assess the realizability of our capitalized customer acquisition costs . for the years ended december 31 , 2012 , 2011 and 2010 , impairments of customer acquisition costs were immaterial . idexx vetlab ® instrument marketing programs . our instrument marketing programs require the customer to enroll at the time of instrument purchase and offer customers the opportunity to earn incentives in future periods based on the volume of the products they purchase and utilize over the term of the program . these arrangements are considered meas in accordance with our revenue recognition policy stated above . revenue reductions related to instrument marketing programs are recorded based on an estimate of customer purchase and utilization levels and the incentive the customer will earn over the term of the program . our estimates are based on historical experience and the specific terms and conditions of the marketing program and require us to apply judgment to approximate future product purchases and utilization . differences between our estimates and actual incentives earned are accounted for as a change in estimate . these differences were not material for the years ended december 31 , 2012 , 2011 and 2010. at 36 december 31 , 2012 , a 5 % change in our estimate of future customer utilization would increase or reduce revenue by approximately $ 0.3 million . reagent rental programs . our reagent rental programs provide our customers the right to use our instruments in consideration for multi-year agreements to purchase annual minimum amounts of consumables . no instrument revenue is recognized at the time of instrument installation . we recognize a portion of the revenue allocated to the instrument concurrent with the future sale of consumables . we determine the amount of revenue allocated from the consumable to the instrument based on vsoe and determine the rate of instrument revenue recognition in proportion to the customer 's minimum volume commitment . the cost of the instrument is reclassified from inventory to equipment and charged to cost of product revenue on a straight-line basis over the term of the rental agreement . idexx points may be applied against the purchase price of idexx products and services purchased in the future or applied to trade receivables due to us . idexx points that have not yet been used by customers are classified as a liability until use or expiration occurs . we estimate the amount of idexx points expected to expire , or breakage , based on historical expirations and we recognize the estimated benefit of breakage as idexx points are issued to customers . on november 30 of each year , unused idexx points earned before january 1 of the prior year generally expire and any variance from the breakage estimate is accounted for as a change in estimate . this variance was not material for the years ended december 31 , 2012 , 2011 and 2010. future market conditions and changes in product offerings may cause us to change marketing strategies to increase or decrease customer incentive offerings , possibly resulting in incremental reductions of revenue in future periods as compared to reductions in the current or prior periods . additionally , certain customer programs require us to estimate , based on historical experience , and apply judgment to approximate the number of customers who will actually redeem the incentive . in determining estimated revenue reductions we utilize data supplied from distributors and collected directly from end-users , which includes the volume of qualifying products purchased and the number of qualifying tests run as reported to us by end-users via idexx smartservice tm , a secure i nternet link that enables us to extract data and provide diagnostic service and support for certain idexx vetlab ® instruments through remote access . differences between estimated and actual customer participation in programs may impact the amount and timing of revenue recognition . following is a summary of revenue reductions , net recorded in connection with our customer programs for the years ended december 31 , 2012 , 2011 and 2010 ( in thousands ) : replace_table_token_4_th 37 at december 31 , 2012 , 2011 and 2010 , the total accrued revenue reductions were $ 36.6 million , $ 37.8 million and $ 23.3 million , respectively . accrued customer programs are included within accrued liabilities and other long-term liabilities , depending on the anticipated settlement date , in the consolidated balance sheets included in this annual report on form 10-k. following is a summary of changes in the accrual for estimated revenue reductions attributable to customer marketing and incentive programs and the ending accrued customer programs balance for the years ended december 31 , 2012 , 2011 and 2010 ( in thousands ) : replace_table_token_5_th inventory valuation we write down the carrying value of inventory for estimated obsolescence by an amount equal to the difference between the cost of inventory and the estimated market value when warranted based on assumptions of future demand , market conditions , remaining shelf life , or product functionality . if actual market conditions or results of estimated functionality are less favorable than those we estimated , additional inventory write-downs may be required , which would have a negative effect on results of operations . valuation of goodwill and other intangible assets a significant portion of the purchase price for acquired businesses is generally assigned to intangible assets . intangible assets other than goodwill are initially valued at fair value . if a quoted price in an active market for the identical asset is not readily available at the measurement date , the fair value of the intangible asset

